These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17383303)

  • 1. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
    Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
    Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ
    Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
    Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
    Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
    Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients.
    Trivedi H; Xiang Q; Klein JP
    Nephrol Dial Transplant; 2009 Jan; 24(1):258-66. PubMed ID: 18682489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M; Malmberg K; Ohrvik J; Rydén L;
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
    Scheen AJ; Legrand V
    Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry.
    Bair TL; Muhlestein JB; May HT; Meredith KG; Horne BD; Pearson RR; Li Q; Jensen KR; Anderson JL; Lappé DL
    Circulation; 2007 Sep; 116(11 Suppl):I226-31. PubMed ID: 17846308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
    Bunch TJ; Muhlestein JB; Bair TL; Renlund DG; Lappé DL; Jensen KR; Horne BD; Carter MA; Anderson JL;
    Am J Cardiol; 2005 Apr; 95(7):827-31. PubMed ID: 15781009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for benefits of perindopril in hypertension and its complications.
    Laurent S
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
    Mackay JA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
    Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
    Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.